Rifampicin 纯度:98.03% 50g

您好！欢迎来到炼石商城请登录注册兼职小伙伴

我的购物车

Qiagen 凯杰 Biosharp Omega

客服热线 0771-3293894

首页酶、辅酶及抑制剂MCE>

图片仅供参考，请以实物为准

Rifampicin 纯度:98.03% 50g

市场价：: 0.00

促销价：: ¥0.00

货号：HY-B0272

品牌：MCE

配送至：

北京朝阳

支付：账期货到付款

数量：

支 (预计4-5工作日到货(以MCE官网货期为准))

亲，想了解价格请QQ咨询客服！

工作时间

周一至周五：9:00-18:00

咨询电话

0771-3293894

在线咨询

: 客服郭恒蔡玉坤曾宪飞技术咨询

浏览了该商品的用户最终购买

RNeasy Mini Kit (50) 50次

3720.00

10ul吸头，透明，袋装，可灭菌...

85.80

UltraSignal 超敏ECL化学发光...

686.00

浏览了该商品的用户还浏览了

QIAfilter Plasmid Maxi Kit (...

3000.00

QIAamp DNA Blood Midi Kit (2...

2680.00

QIAamp UCP Pathogen Mini Kit...

4112.00

商品介绍
商品咨询

Rifampicin 是一种光谱抗生素，能够抑制细菌的 DNA 依赖性 RNA 聚合酶的活性。

Description

Rifampicin is a broad-spectrum antibiotic, which inhibits the bacterial DNA-dependent RNA polymerase.

In Vitro

Rifampicin (100 mg/mL) can block the functional activity of P-glycoprotein. Rifampicin is not a substract for P-glycoprotein. The mechanism of rifampicin resistance is unassociated with the functional activity of P-glycoprotein^[3].

In Vivo

Rifampicin (200, 400 mg/kg) can induce fatty liver at high concentration^[1]. Rifampicin (30 mg/kg, i.p.) treatment of S464P biofilms in vivo results in a slight decline, but earlier rebinds in bioluminescence from these catheters compared with the parental signal, whereas rifampicin has no affect on bioluminescence in mice infected with mutant H481Y^[2].

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (60.76 mM; Need ultrasonic)

H₂O : < 0.1 mg/mL (insoluble)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.2152 mL	6.0758 mL	12.1516 mL
5 mM	0.2430 mL	1.2152 mL	2.4303 mL
10 mM	0.1215 mL	0.6076 mL	1.2152 mL

* Please refer to the solubility information to select the appropriate solvent.

In Vivo:

1.

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in saline)

Solubility: ≥ 2.5 mg/mL (3.04 mM); Clear solution
2.

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% saline

Solubility: 2.5 mg/mL (3.04 mM); Clear solution; Need ultrasonic

References

[1]. Piriou A, et al. Fatty liver induced by high doses of rifampicin in the rat: possible relation with an inhibition of RNA polymerases in eukariotic cells. Arch Toxicol Suppl. 1979;(2):333-7.

[2]. Yu J, et al. Monitoring in vivo fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model. J Antimicrob Chemother. 2005 Apr;55(4):528-34. Epub 2005 Mar 2.

[3]. Erokhina MV, et al. [In vitro development of rifampicin resistance in the epithelial cells]. Probl Tuberk Bolezn Legk. 2006;(8):58-61.

Animal Administration ^[2]	Briefly, 1 cm Teflon catheter (14-gauge) carrying 104 cfu S. aureus, either the parental strain Xen 29 or the RifR mutants S464P or H481Y, are implanted subcutaneously in groups of nine mice per strain. One catheter segment is inserted on each side of each animal. Six days after the implantation of the catheters, five mice from each group are treated with rifampicin at 30 mg/kg intraperitoneally in 0.1 mL saline, twice daily for four consecutive days. The remaining four mice in each group are left untreated as controls. At various time points during the infection, the mice are anaesthetized using a constant flow of 1.5% isoflurane from the IVIS^® manifold, and imaged using an IVIS^® Image System 100 Series. The bioluminescent signals (photons/s) emitted from the mice are analysed using LivingImage^® software and plotted over the course of infection. The mice are sacrificed 20 days after infection (11 days after final rifampicin treatment). The catheters are surgically removed and the bacteria are detached by sonication for determination of bacterial burdens on the catheters. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Piriou A, et al. Fatty liver induced by high doses of rifampicin in the rat: possible relation with an inhibition of RNA polymerases in eukariotic cells. Arch Toxicol Suppl. 1979;(2):333-7. [2]. Yu J, et al. Monitoring in vivo fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model. J Antimicrob Chemother. 2005 Apr;55(4):528-34. Epub 2005 Mar 2. [3]. Erokhina MV, et al. [In vitro development of rifampicin resistance in the epithelial cells]. Probl Tuberk Bolezn Legk. 2006;(8):58-61.

Animal Administration
^[2]

Briefly, 1 cm Teflon catheter (14-gauge) carrying 104 cfu S. aureus, either the parental strain Xen 29 or the RifR mutants S464P or H481Y, are implanted subcutaneously in groups of nine mice per strain. One catheter segment is inserted on each side of each animal. Six days after the implantation of the catheters, five mice from each group are treated with rifampicin at 30 mg/kg intraperitoneally in 0.1 mL saline, twice daily for four consecutive days. The remaining four mice in each group are left untreated as controls. At various time points during the infection, the mice are anaesthetized using a constant flow of 1.5% isoflurane from the IVIS^® manifold, and imaged using an IVIS^® Image System 100 Series. The bioluminescent signals (photons/s) emitted from the mice are analysed using LivingImage^® software and plotted over the course of infection. The mice are sacrificed 20 days after infection (11 days after final rifampicin treatment). The catheters are surgically removed and the bacteria are detached by sonication for determination of bacterial burdens on the catheters.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

References

[1]. Piriou A, et al. Fatty liver induced by high doses of rifampicin in the rat: possible relation with an inhibition of RNA polymerases in eukariotic cells. Arch Toxicol Suppl. 1979;(2):333-7.

[2]. Yu J, et al. Monitoring in vivo fitness of rifampicin-resistant Staphylococcus aureus mutants in a mouse biofilm infection model. J Antimicrob Chemother. 2005 Apr;55(4):528-34. Epub 2005 Mar 2.

[3]. Erokhina MV, et al. [In vitro development of rifampicin resistance in the epithelial cells]. Probl Tuberk Bolezn Legk. 2006;(8):58-61.

Molecular Weight

822.94

Formula

C₄₃H₅₈N₄O₁₂

CAS No.

13292-46-1

SMILES

OC(C(/C=N/N1CCN(C)CC1)=C(NC(/C(C)=C\C=C\[C@@H]([C@@H]([C@@H](C)[C@H]2O)O)C)=O)C(O)=C3C(O)=C4C)=C3C5=C4O[C@](C)(O/C=C/[C@@H]([C@H]([C@@]([C@@H]2C)([H])OC(C)=O)C)OC)C5=O

Storage